Related Articles
suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: An EORTC Receptor and Biomarker Group collaboration
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: Comparison to antigen quantification by ELISA
EXPRESSION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) AND ITS RECEPTOR (UPAR) IN HUMAN OVARIAN-CANCER CELLS AND IN-VITRO INVASION CAPACITY
Tissue urokinase-type plasminogen activator receptor levels in breast cancer.